Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $51.60 Consensus Price Target from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus recommendation of "Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $51.60.

A number of research firms recently weighed in on TARS. Oppenheimer reissued an "outperform" rating and issued a $63.00 price objective (up from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. TFG Asset Management GP Ltd raised its position in Tarsus Pharmaceuticals by 30.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 800,000 shares of the company's stock valued at $16,200,000 after purchasing an additional 185,000 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Tarsus Pharmaceuticals by 2.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 192,303 shares of the company's stock valued at $6,990,000 after purchasing an additional 4,889 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Tarsus Pharmaceuticals by 71.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,567 shares of the company's stock valued at $239,000 after purchasing an additional 2,735 shares in the last quarter. Jennison Associates LLC purchased a new position in shares of Tarsus Pharmaceuticals in the 1st quarter valued at $48,380,000. Finally, Quantbot Technologies LP purchased a new position in shares of Tarsus Pharmaceuticals in the 1st quarter valued at $410,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Price Performance

Shares of TARS traded up $0.77 during trading hours on Thursday, reaching $35.50. 607,368 shares of the stock traded hands, compared to its average volume of 702,126. The company has a market cap of $1.35 billion, a P/E ratio of -7.44 and a beta of 1.07. Tarsus Pharmaceuticals has a 52-week low of $12.57 and a 52-week high of $42.50. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The company's 50-day moving average price is $29.10 and its two-hundred day moving average price is $31.08.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The company had revenue of $40.81 million during the quarter, compared to analyst estimates of $31.30 million. During the same period in the previous year, the firm earned ($1.17) earnings per share. On average, analysts anticipate that Tarsus Pharmaceuticals will post -3.68 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.